157 related articles for article (PubMed ID: 11344190)
1. Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up.
MacFarlane CE; Brown DC; Johnston LB; Patton MA; Dunger DB; Savage MO; McKenna WJ; Kelnar CJ
J Clin Endocrinol Metab; 2001 May; 86(5):1953-6. PubMed ID: 11344190
[TBL] [Abstract][Full Text] [Related]
2. The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome.
Cotterill AM; McKenna WJ; Brady AF; Sharland M; Elsawi M; Yamada M; Camacho-Hübner C; Kelnar CJ; Dunger DB; Patton MA; Savage MO
J Clin Endocrinol Metab; 1996 Jun; 81(6):2291-7. PubMed ID: 8964866
[TBL] [Abstract][Full Text] [Related]
3. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
[TBL] [Abstract][Full Text] [Related]
4. Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone.
Romano AA; Dana K; Bakker B; Davis DA; Hunold JJ; Jacobs J; Lippe B
J Clin Endocrinol Metab; 2009 Jul; 94(7):2338-44. PubMed ID: 19401366
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial.
Noordam C; Van der Burgt I; Sengers RC; Delemarre-van de Waal HA; Otten BJ
Acta Paediatr; 2001 Aug; 90(8):889-94. PubMed ID: 11529537
[TBL] [Abstract][Full Text] [Related]
6. [Calcium-phosphate metabolism and bone markers in two patients with Noonan's syndrome treated with growth hormone].
Praticò G; Palano GM; Lo Presti D; Parisi G; Caruso-Nicoletti M
Minerva Pediatr; 2003 Dec; 55(6):593-8. PubMed ID: 14676730
[TBL] [Abstract][Full Text] [Related]
7. Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency.
Zavras N; Meazza C; Pilotta A; Gertosio C; Pagani S; Tinelli C; Bozzola M
Ital J Pediatr; 2015 Oct; 41():71. PubMed ID: 26444854
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone therapy in Noonan's syndrome: non-cardiomyopathic congenital heart disease does not adversely affect growth improvement.
Brown DC; Macfarlane CE; McKenna WJ; Patton MA; Dunger DB; Savage MO; Kelnar CJ
J Pediatr Endocrinol Metab; 2002 Jun; 15(6):851-2. PubMed ID: 12099396
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial.
Blum WF; Crowe BJ; Quigley CA; Jung H; Cao D; Ross JL; Braun L; Rappold G;
J Clin Endocrinol Metab; 2007 Jan; 92(1):219-28. PubMed ID: 17047016
[TBL] [Abstract][Full Text] [Related]
10. Increased response, but lower responsiveness, to growth hormone (GH) in very young children (aged 0-3 years) with idiopathic GH Deficiency: analysis of data from KIGS.
Ranke MB; Lindberg A; Albertsson-Wikland K; Wilton P; Price DA; Reiter EO
J Clin Endocrinol Metab; 2005 Apr; 90(4):1966-71. PubMed ID: 15634724
[TBL] [Abstract][Full Text] [Related]
11. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome.
Binder G; Neuer K; Ranke MB; Wittekindt NE
J Clin Endocrinol Metab; 2005 Sep; 90(9):5377-81. PubMed ID: 15985475
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.
Kamp GA; Mul D; Waelkens JJ; Jansen M; Delemarre-van de Waal HA; Verhoeven-Wind L; Frölich M; Oostdijk W; Wit JM
J Clin Endocrinol Metab; 2001 Jul; 86(7):2969-75. PubMed ID: 11443153
[TBL] [Abstract][Full Text] [Related]
13. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group.
MacGillivray MH; Baptista J; Johanson A
J Clin Endocrinol Metab; 1996 May; 81(5):1806-9. PubMed ID: 8626839
[TBL] [Abstract][Full Text] [Related]
14. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children.
Binder G; Baur F; Schweizer R; Ranke MB
J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706
[TBL] [Abstract][Full Text] [Related]
15. A 5-year prospective study of growth hormone (GH)-deficient children treated with GH before the age of 3 years. French Serono Study Group.
Rappaport R; Mugnier E; Limoni C; Crosnier H; Czernichow P; Leger J; Limal JM; Rochiccioli P; Soskin S
J Clin Endocrinol Metab; 1997 Feb; 82(2):452-6. PubMed ID: 9024235
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia.
Quintos JB; Vogiatzi MG; Harbison MD; New MI
J Clin Endocrinol Metab; 2001 Apr; 86(4):1511-7. PubMed ID: 11297576
[TBL] [Abstract][Full Text] [Related]
17. Linear growth and final height after treatment for Cushing's disease in childhood.
Lebrethon MC; Grossman AB; Afshar F; Plowman PN; Besser GM; Savage MO
J Clin Endocrinol Metab; 2000 Sep; 85(9):3262-5. PubMed ID: 10999819
[TBL] [Abstract][Full Text] [Related]
18. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study.
Ranke MB; Lindberg A; Chatelain P; Wilton P; Cutfield W; Albertsson-Wikland K; Price DA
J Clin Endocrinol Metab; 1999 Apr; 84(4):1174-83. PubMed ID: 10199749
[TBL] [Abstract][Full Text] [Related]
19. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years.
de Zegher F; Du Caju MV; Heinrichs C; Maes M; De Schepper J; Craen M; Vanweser K; Malvaux P; Rosenfeld RG
J Clin Endocrinol Metab; 1999 May; 84(5):1558-61. PubMed ID: 10323379
[TBL] [Abstract][Full Text] [Related]
20. Effects of growth hormone treatment on left ventricular dimensions in children with Noonan's syndrome.
Noordam C; Draaisma JM; van den Nieuwenhof J; van der Burgt I; Otten BJ; Daniels O
Horm Res; 2001; 56(3-4):110-3. PubMed ID: 11847472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
